Skip to main content
. 2021 Nov 3;3(1):100181. doi: 10.1016/j.xinn.2021.100181

Figure 2.

Figure 2

The neutralizing activity of the convalescents' sera to SARS-CoV-2 variants

(A) The amino acid alterations in the S protein of SARS-CoV-2 variants tested in this study.

(B) The neutralizing activity of convalescents' sera at 100-fold dilution against pseudoviruses bearing S proteins from the indicated variants with WT-D614G as a control.

(C–E) Paired analysis of NT50 values of convalescents' sera or RBD-vaccinated mice sera against WT-D614G and variants. Serum group 1, relatively resistant (C). Serum group 2, sensitive (D). RBD-vaccinated mice sera (E). Serum groups 1 and 2 were selected according to their tolerance to B.1.351 pseudovirus. Statistical significance was determined using paired two-tailed t tests. p values and mean fold changes in NT50 values compared with WT-D614G are indicated.

(F) The neutralizing activity of convalescents' sera at 100-fold dilution against pseudoviruses bearing different S with the indicated mutations. (★) The relatively resistant serum sample; (•) the sensitive serum sample.